MPO and cancer: Several new potential biomarkers, such as C-reactive protein (CRP), soluble suppression of tumorigenicity 2 (sST2), galectin-3 (Gal-3), myeloperoxidase (MPO), placental growth factor (PIGF), tumor growth differentiation factor (GDF-15), and microRNAs, hold promise for predicting cardiovascular disease not only in cancer patients but in cases of other chronic diseases [24,25].